Vascular endothelial growth factor −634G/C polymorphism is associated with increased breast cancer risk and aggressiveness

Sa-nguanraksa, Doonyapat; Chuangsuwanich, Tuenjai; Pongpruttipan, Tawatchai; Kummalue, Tanawan; Rojananin, Supakorn; Ratanawichhitrasin, Adune; Prasarttong-Osoth, Poramaporn; Chuthatisith, Suebwong; Pisarnturakit, Pongthep; Aeumrithaicharoenchok, W.; Rushatamukayanunt, Pradit; Lohsiriwat, Visnu; Boonsripitayanon, Mongkol; Malasit, Prida; O-charoenrat, Pornchai

doi:10.3892/mmr.2013.1607

Cited by 27 publications

(40 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results suggest that the VEGF-2578C/A and -1154G/A polymorphisms do not play a major role in the carcinogenesis of HCC. The VEGF-2578C/A and -1154G/A polymorphisms have been associated with decreased risk and aggressiveness of certain cancers (Tamura et al, 2012;Sa-Nguanraksa et al, 2013), showing conflicting results to those of our study. This finding is biologically plausible, particularly in light of the putative function of these polymorphisms.…”

Section: Discussioncontrasting

confidence: 56%

“…DNA sequence variations in the VEGF gene may alter VEGF production and/or activity, thereby causing interindividual differences in susceptibility to lung cancer because of their effects on tumor angiogenesis pathways. VEGF polymorphisms have been studied in relation to risk and histopathological characteristics of various cancers with disparate results (Koukourakis et al, 2004;Chien et al, 2013;Luo et al, 2013;Oh et al, 2013;Sa-Nguanraksa et al, 2013;Wu et al, 2013b). Four common SNPs, -2578C/A, -1154G/A, -634C/G, and -1498T/C, have been reported to be significantly associated with VEGF protein production (Koukourakis et al, 2004;Oh et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Polymorphisms of vascular endothelial growth factor on prognosis in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization treatment

Song¹,

Wang²,

Li³

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We conducted a cohort study to investigate the prognostic significance of vascular endothelial growth factor (VEGF) polymorphisms in hepatocellular carcinoma (HCC) patients after transcatheter arterial chemoembolization (TACE). In total, 156 patients with histologically confirmed HCC within 2 months were collected from January 2007 to January 2008. The genotypes of VEGF-2578C/A, -1154G/A, -634C/G, and -1498T/C were determined from blood extracted using a blood kit on a 384-well plate. The survival rate at 5 years was 55.47%. Multivariate analysis revealed that only tumornode-metastasis (TNM) stage, metastasis, and the VEGF-2578 AA and -1154 AA genotypes were independent prognostic factors. Patients with TNM stage III-IV and metastasis showed a greatly increased risk of death from HCC, with hazard ratios (HRs) [95% confidence interval (CI)] of 3.64 (1.67-6.79) and 2.91 (1.30-6.27), respectively. Moreover, the VEGF-2578 AA and -1154 AA genotypes showed a significantly increased risk of death compared with the wild-type genotype (HR 8947 ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 13 (4): 8946-8953 (2014) VEGF polymorphism and HCC prognosis = 3.65, 95%CI = 1.35-11.13; HR = 7.13, 95%CI = 1.46-65.8). These results will be helpful for predicting clinical outcomes of HCC patients.

show abstract

Section: Discussioncontrasting

confidence: 56%

Section: Discussionmentioning

confidence: 99%

Polymorphisms of vascular endothelial growth factor on prognosis in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization treatment

Song¹,

Wang²,

Li³

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…R015332015 and included 100 mastectomy cases with adequate material for study. All cases were obtained during 2002-2004 from the Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University previously enrolled in the study of 'The role of the vascular endothelial growth factor polymorphisms in Thai breast cancer patients (Sa-Nguanraksa et al, 2013).…”

Section: Methodsmentioning

confidence: 99%

Clinicopathologic Features of Breast Carcinomas Classified by Biomarkers and Correlation with Microvessel Density and VEGF Expression: A Study from Thailand

Chuangsuwanich¹,

Pongpruttipan²,

O-charoenrat³

et al. 2014

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

“…Previous studies have reported that -634G/C polymorphism is associated with the clinical outcome of breast, gastric, prostate and ovarian cancers (33)(34)(35)(36). One study investigated the association between VEGF polymorphism and the prognosis of osteosarcoma, but this previous study did not identify that the -634G/C polymorphism played a role in the clinical outcome of osteosarcoma (37).…”

Section: Discussionmentioning

confidence: 60%

Role of five small nucleotide polymorphisms in the VEGF gene on the susceptibility to osteosarcoma and overall survival of patients

Liu¹,

Bai²,

Duan³

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The present study aimed to investigate the association between five common small nucleotide polymorphisms (SNPs) in the VEGF gene and the risk of osteosarcoma. An additional aim was to investigate the role of these five SNPs on the prognosis of osteosarcoma. A total of 186 patients with osteosarcoma and 186 age-and sex-matched healthy controls were enrolled into the present study. A polymerase chain reaction-restriction fragment length polymorphism assay was conducted to determine the incidence of the VEGF-2578 C/A, -1156 G/A, +1612 G/A, +936 C/T and -634 G/C polymorphisms. Conditional logistic regression analyses revealed that individuals carrying the -634 GG genotype possessed a significantly increased risk of osteosarcoma, with an adjusted odds ratio [(95% confidence interval (CI)] of 2.00 (1.07-3.75). In the Cox proportional hazards model, subsequent to adjusting for potential confounding factors, patients with osteosarcoma carrying the -634 GG genotype were found to demonstrate a shorter overall survival time (hazard ratio, 3.10; 95% CI, 1.17-8.38). The VEGF-634 G/C polymorphism may therefore be used as a genetic marker for the prediction of the risk and clinical outcome of osteosarcoma. IntroductionOsteosarcoma is derived from mesenchymal tissues and often occurs in the distal femur, proximal tibia and humeral metaphysis. Osteosarcoma is one of the most common malignant tumors in children and adolescents. It is estimated that the annual incidence of osteosarcoma is 4-5 cases per 1,000,000 individuals worldwide, and osteosarcoma is a leading cause of cancer-associated mortalities in children and young adults (1-3).The development of osteosarcoma is a complex, multistep and multifactorial process in which numerous factors are implicated (4-6). Several studies have been performed to investigate cancer stem cells and the potential of these cells to cause tumors (7,8). The concept that genetic factors are involved in the development of osteosarcoma has led to numerous studies investigating genetic determinants for osteosarcoma in the past decade (10-13).Vascular endothelial growth factor (VEGF) is one of the most potent endothelial cell mitogens, and performs an important role in angiogenesis (14,15). The VEGF gene, which consists of eight exons that undergo alternative splicing to form a family of proteins, is located at chromosome 6p21.3. It is well known that the VEGF gene results in several alternatively spliced isoforms, and the regulation of VEGF expression can reveal the difference between normal and tumor tissues. It is estimated that there are >30 types of single nucleotide polymorphism (SNP) in the VEGF gene (16), and several SNPs in the VEGF gene have been reported to affect the expression of the VEGF gene (16). Among these SNPs, five common SNPs in the VEGF gene, consisting of -2578C/A, -1156G/A, +1612G/A, +936C/T and -634G/C, are reported to be associated with VEGF protein synthesis (17). The -2578C/A and -1156G/A SNPs are located at the VEGF promoter region, and the +1612G/A, +936C/T and...

show abstract

Vascular endothelial growth factor −634G/C polymorphism is associated with increased breast cancer risk and aggressiveness

Cited by 27 publications

References 24 publications

Polymorphisms of vascular endothelial growth factor on prognosis in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization treatment

Polymorphisms of vascular endothelial growth factor on prognosis in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization treatment

Clinicopathologic Features of Breast Carcinomas Classified by Biomarkers and Correlation with Microvessel Density and VEGF Expression: A Study from Thailand

Role of five small nucleotide polymorphisms in the VEGF gene on the susceptibility to osteosarcoma and overall survival of patients

Contact Info

Product

Resources

About